A multi-center, randomized, double-blind, double-dummy, vehicle-controlled sequential cohort study to determine the safety PEP005 [ingenol mebutate] 0.025% and 0.05% topical gel in patients with actinic keratosis

Trial Profile

A multi-center, randomized, double-blind, double-dummy, vehicle-controlled sequential cohort study to determine the safety PEP005 [ingenol mebutate] 0.025% and 0.05% topical gel in patients with actinic keratosis

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Peplin
  • Most Recent Events

    • 06 Jun 2009 Primary endpoint 'Partial clinical response rate' has been met.
    • 06 Jun 2009 Results have been published in the Journal of the American Academy of Dermatology.
    • 05 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top